Kalyra Pharmaceuticals Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 23
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $4.5M
Latest Deal Amount
  • Investors
  • 7

Kalyra Pharmaceuticals General Information

Description

Developer of medicines designed to address unmet needs in the area of pain management, anti-infectives and fibrosis. The company's medicines are potent, non-opioid, non-NSAID pain therapeutics that are made using modified molecules that retain the efficacy of commonly used medications while reducing or eliminating unwanted side effects and safety concerns, enabling doctors to improve patient outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 10835 Road To The Cure
  • Suite 205
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kalyra Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Corporate (Series B) 21-Dec-2017 $4.5M 000.00 0000 Completed Startup
4. Grant 01-Jan-2017 000000 00.000 Completed Startup
3. Grant 01-Jan-2016 00000 00.000 Completed Startup
2. Grant 01-Jan-2015 $2.47M $6.18M Completed Startup
1. Early Stage VC (Series A) 08-Nov-2013 $6.18M $6.18M 000.00 Completed Startup
To view Kalyra Pharmaceuticals’s complete valuation and funding history, request access »

Kalyra Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.00 00.00 00 00.00 00.000
To view Kalyra Pharmaceuticals’s complete cap table history, request access »

Kalyra Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
Kevin Bunker Ph.D Co-Founder, Chief Executive Officer, Chief Scientific Officer and Board Member
Cam Garner Co-Founder and Executive Chairman
Deborah Slee Ph.D Senior Vice President, Research & Development
Cam Gallagher Chief Business Officer
Brian Dorsey Co-Founder
You’re viewing 5 of 6 executive team members. Get the full list »

Kalyra Pharmaceuticals Board Members (5)

Name Representing Role Since
Cam Garner Kalyra Pharmaceuticals Co-Founder and Executive Chairman 000 0000
Dirk Thye MD Self Board Member 000 0000
Kevin Bunker Ph.D Kalyra Pharmaceuticals Co-Founder, Chief Executive Officer, Chief Scientific Officer and Board Member 000 0000
Ned Israelsen JD Kalyra Pharmaceuticals Board Member 000 0000
Scott Glenn Windamere Venture Partners Board Member 000 0000
To view Kalyra Pharmaceuticals’s complete board members history, request access »

Kalyra Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kalyra Pharmaceuticals Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Zentalis Pharmaceuticals Corporation Minority 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Sergio Gurrieri Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »